Multiple Myeloma – Unmet Need – Unmet Need – Third- and Fourth-Line Multiple Myeloma (US/EU)
The treatment of multiple myeloma is complex, often involving combinations of CD38-blocking monoclonal antibodies (MAbs), immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), chemotherapy, and corticosteroids across lines of therapy. Due to a lack of treatment options, regimens used to treat third and fourth-line multiple myeloma often include drugs that are also used in earlier lines of treatment. Consequently, third- and fourth-line patients may be refractory to CD38-blocking MAbs, lenalidomide, or bortezomib, highlighting the need for therapies with novel targets. The label expansion of the anti-BCMA CAR T-cell therapies, Bristol Myers Squibb / Bluebird Bio’s Abecma and Johnson & Johnson / Legend Biotech’s Carvykti, into third- and fourth-lines of therapy has partially addressed this issue. However, the recurring nature of multiple myeloma underscores the need for more efficacious treatments.
Questions answered
- Which attributes most influence physicians’ prescribing decisions in the treatment of third- and fourth-line multiple myeloma?
- How do hematologist-oncologist rate the performance of current monotherapies and regimens, such as CAR T-cell therapies, on key treatment drivers and goals for this patient population?
- What are the prevailing areas of unmet need in the treatment of third- and fourth-line multiple myeloma?
- What trade-offs across different clinical attributes and price are acceptable to surveyed hematologist-oncologists for a hypothetical treatment of third- and fourth-line multiple myeloma?
Geography: United States, France, Germany, United Kingdom
Primary research: Survey of 60 U.S. and 33 European hematologist-oncologists
Key drugs covered: Darzalex Faspro, Kyprolis, Pomalyst / Imnovid, Carvykti, and Abecma
Key feature: Target Product Profile (TPP) simulator tool allows for customizable market simulations based on conjoint analysis. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.
Product description
Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:
- Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians’ weightings and analysis of stated vs. derived importance.
- Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.
- Analyze market scenarios for different target product profiles using the TPP Simulator.
